Revenue
No reported data
ZyVersa Therapeutics, Inc. (ZVSA)
Price—Loading quote
Net income
2023
2024
2025
Free cash flow
No reported data
Total cash / debt
CashTotal debt
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Research & development | $1.1M | $1.8M | $3.2M |
| Operating expenses | $25.5M | $9.1M | $107.8M |
| Operating income | −$25.5M | −$9.1M | −$107.8M |
| Net income | −$25.0M | −$9.4M | −$98.3M |
| Basic EPSper diluted share | -$4.18 | -$8.48 | -$1,089.70 |
| Diluted EPSper diluted share | -$4.18 | -$8.48 | -$1,089.70 |